PL366119A1 - Leczenie zaburzeń lękowych - Google Patents

Leczenie zaburzeń lękowych

Info

Publication number
PL366119A1
PL366119A1 PL01366119A PL36611901A PL366119A1 PL 366119 A1 PL366119 A1 PL 366119A1 PL 01366119 A PL01366119 A PL 01366119A PL 36611901 A PL36611901 A PL 36611901A PL 366119 A1 PL366119 A1 PL 366119A1
Authority
PL
Poland
Prior art keywords
treatment
anxiety disorders
anxiety
disorders
Prior art date
Application number
PL01366119A
Other languages
English (en)
Inventor
Holly Read Thomasson
David Michelson
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of PL366119A1 publication Critical patent/PL366119A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
PL01366119A 2000-11-15 2001-11-06 Leczenie zaburzeń lękowych PL366119A1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24901000P 2000-11-15 2000-11-15
US26536201P 2001-01-31 2001-01-31

Publications (1)

Publication Number Publication Date
PL366119A1 true PL366119A1 (pl) 2005-01-24

Family

ID=26939750

Family Applications (1)

Application Number Title Priority Date Filing Date
PL01366119A PL366119A1 (pl) 2000-11-15 2001-11-06 Leczenie zaburzeń lękowych

Country Status (16)

Country Link
EP (1) EP1395253A2 (pl)
JP (1) JP2004529073A (pl)
KR (1) KR20030051812A (pl)
CN (1) CN1822825A (pl)
AU (1) AU2002217757A1 (pl)
BR (1) BR0115301A (pl)
CA (1) CA2426069A1 (pl)
CZ (1) CZ20031339A3 (pl)
EA (1) EA200300567A1 (pl)
HR (1) HRP20030384A2 (pl)
IL (1) IL155874A0 (pl)
MX (1) MXPA03004190A (pl)
NO (1) NO20032156L (pl)
PL (1) PL366119A1 (pl)
SK (1) SK5422003A3 (pl)
WO (1) WO2002040006A2 (pl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200705146T1 (tr) * 2001-03-06 2008-02-21 Eli Lilly And Company Monoamin Yükselmesinin Engellenmesi
BR0313411A (pt) * 2002-08-14 2005-06-28 Pharmacia & Upjohn Co Llc Uso de reboxetina para o tratamento de ondas de calor
GB0309440D0 (en) * 2003-04-25 2003-06-04 Lilly Co Eli Quinolone derivatives
WO2004103356A2 (en) * 2003-05-15 2004-12-02 Eli Lilly And Company Treatment of emotional dysregulation
ATE399557T1 (de) * 2003-12-12 2008-07-15 Lilly Co Eli Selektive norepinephrin-wiederaufnahmehemmer zur behandlung von hitzewallungen
WO2009089479A2 (en) 2008-01-09 2009-07-16 Mayo Foundation For Medical Education And Research Inhibiting neurotransmitter reuptake
WO2011056788A2 (en) * 2009-11-03 2011-05-12 Mayo Foundation For Medical Education And Research Inhibiting neurotransmitter reuptake
US20120220665A1 (en) * 2009-11-03 2012-08-30 Mayo Foundation For Medical Education And Research Inhibiting Neurotransmitter Reuptake
WO2014159251A2 (en) 2013-03-14 2014-10-02 Mayo Foundation For Medical Education And Research Inhibiting neurotransmitter reuptake
CN119174751A (zh) * 2019-02-01 2024-12-24 霍夫曼技术有限责任公司 用于治疗焦虑相关病症的组合物和方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997041878A1 (en) * 1996-05-07 1997-11-13 Merck & Co., Inc. Treatment of mood disorders with a growth hormone secretagogue
IT1305322B1 (it) * 1998-04-23 2001-05-04 Pharmacia & Upjohn Spa Uso di reboxetina per il trattamento di disturbi nervosi
DE60035232T2 (de) * 1999-07-01 2008-02-14 Pharmacia & Upjohn Co. Llc, Kalamazoo (S,S)-Reboxetin zur Behandlung von chronischem Müdigkeits-Syndrom

Also Published As

Publication number Publication date
HRP20030384A2 (en) 2003-08-31
IL155874A0 (en) 2003-12-23
JP2004529073A (ja) 2004-09-24
CA2426069A1 (en) 2002-05-23
CN1822825A (zh) 2006-08-23
KR20030051812A (ko) 2003-06-25
BR0115301A (pt) 2004-12-14
SK5422003A3 (en) 2003-12-02
CZ20031339A3 (cs) 2003-10-15
EP1395253A2 (en) 2004-03-10
NO20032156D0 (no) 2003-05-13
WO2002040006A2 (en) 2002-05-23
AU2002217757A1 (en) 2002-05-27
WO2002040006A3 (en) 2003-12-24
EA200300567A1 (ru) 2004-10-28
MXPA03004190A (es) 2003-09-22
NO20032156L (no) 2003-05-13

Similar Documents

Publication Publication Date Title
GB0007193D0 (en) Treatment of movrmrnt disorders
AU8187701A (en) Sulfonyl-pyrrolidine derivatives useful for the treatment of neurological disorders
IL155589A0 (en) Novel amidoalkyl-piperidine and amidoalkyl-piperazine derivatives useful for the treatment of nervous system disorders
AU9527001A (en) Treatment of T cell disorders
AU2002360555A8 (en) Treatment of genitourinary tract disorders
IL155874A0 (en) Treatment of anxiety disorders
IL150479A0 (en) Treatment of psoriasis
IL150290A0 (en) The use of mirtazapine for the treatment of sleep disorders
HUP0102886A3 (en) Treatment of anxiety disorders
GB2360453B (en) Treatment of skin conditions
SI1468686T1 (sl) S-metil-dihidro-ziprazidon za zdravljenje psihiatricnih motenj
IL151493A0 (en) Use of dermaciclane for the treatment of anxiety and depression
GB0010496D0 (en) Treatment of conditions of the central nervous system
EP1303281A4 (en) METHODS OF TREATMENT
HK1063438A (en) Treatment of anxiety disorders
GB0017951D0 (en) Treatment of movement disorders
IL153788A0 (en) Treatment of eating disorders using carboxyalkylethers
GB0003228D0 (en) Treatment of GI disorders
GB0029955D0 (en) Treatment of neuropsychiatric disorders
GB0125371D0 (en) Treatment of movement disorders
GB0021060D0 (en) Treatment of functional gastrointestinal disorders
GB9924942D0 (en) Treatment of movement disorders
GB0014904D0 (en) Methods of treatment
GB0013928D0 (en) Methods of treatment
GB0004998D0 (en) The treatment of functional gastrointestinal disorders

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)